Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- 1 May 2008
- journal article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 83 (5), 584-594
- https://doi.org/10.1016/s0025-6196(11)60735-0
Abstract
No abstract availableThis publication has 97 references indexed in Scilit:
- Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1Nature Genetics, 2008
- Thoracoscopic Lobectomy Is a Safe and Versatile ProcedureAnnals of Surgery, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999